Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core‐binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Allogeneic hematopoietic cell transplantation (allo‐HCT) is recommended for core‐binding factor mutated (CBF) AML patients achieving second complete remission (CR2). However, approximately 20% of patients may relapse after transplant and donor preference remains unclear. We compared in this EBMT glo...

Full description

Saved in:
Bibliographic Details
Published in:American journal of hematology 2024-07, Vol.99 (7), p.1290-1299
Main Authors: Ye, Yishan, Labopin, Myriam, Gérard, Socié, Yakoub‐Agha, Ibrahim, Blau, Igor Wolfgang, Aljurf, Mahmoud, Forcade, Edouard, Gedde‐Dahl, Tobias, Burns, David, Vydra, Jan, Halahleh, Khalid, Hamladji, Rose‐Marie, Bazarbachi, Ali, Nagler, Arnon, Brissot, Eolia, Li, Lin, Luo, Yi, Zhao, Yanmin, Ciceri, Fabio, Huang, He, Mohty, Mohamad, Gorin, Norbert Claude
Format: Article
Language:English
Subjects:
Acute myeloid leukemia
Adolescent
Adult
Aged
Allografts
Bone marrow transplantation
Core Binding Factors - genetics
Donors
Europe
Female
Hematopoietic Stem Cell Transplantation - methods
Hematopoietic stem cells
Humans
Incidence
Leukemia, Myeloid, Acute - genetics
Leukemia, Myeloid, Acute - therapy
Life Sciences
Male
Middle Aged
Multivariate analysis
Recurrence
Registries
Remission
Remission Induction
Runx1 protein
Siblings
Stem cell transplantation
Transplantation, Haploidentical - methods
Unrelated Donors
Young Adult
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Allogeneic hematopoietic cell transplantation (allo‐HCT) is recommended for core‐binding factor mutated (CBF) AML patients achieving second complete remission (CR2). However, approximately 20% of patients may relapse after transplant and donor preference remains unclear. We compared in this EBMT global multicenter registry‐based analysis the allo‐HCT outcomes using either haploidentical (Haplo), matched siblings donors (MSD), or 10/10 matched unrelated donors (MUD). Data from 865 de novo adult CBF AML patients in CR2 receiving allo‐HCT in 227 EBMT centers from 2010 to 2022 were analyzed, in which 329 MSD, 374 MUD, and 162 Haplo‐HCTs were included. For the entire cohort, 503 (58%) patients were inv(16)/CBFB‐MYH11 and 362 patients (42%) were t(8;21)/RUNX1‐RUNX1T1 AML. On multivariate analysis, Haplo‐HCT was associated with a lower Relapse Incidence (RI) compared to either MSD (hazard ratio [HR] = 0.56, 95% CI 0.32–0.97; p 
ISSN:0361-8609
1096-8652
1096-8652
DOI:10.1002/ajh.27342